Today the FDA announced the approval of inclisiran (Leqvio) as a treatment for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional low-density lipoprotein cholesterol (LDL-C) lowering. Inclisiran is an injection administered in the doctor's office twice a year to be used along with diet and maximally tolerated statin therapy and may reduce circulating levels of LDL-C up to 51%.
Related posts:
- FDA Listening Session for HoFH
- ICER Report on Treatments for High Cholesterol – Family Heart Foundation to Comment at Public Meeting February 5
- Why are FH patients paying a higher price for PCSK9 inhibitor treatment when a lower price is available, and what can we do about it?
- New Drug for Homozygous Familial Hypercholesterolemia Approved by the FDA